IYH logo

IYH
iShares US Healthcare ETF

195
Volume
472,565.00
52W High
$67.63
52W Low
$53.94
50D MA
$61.47
Prev Close
$62.29
Loading...
Loading...
News
all
press releases
Goldman Sachs Lifts UnitedHealth Target Price: Healthcare ETFs to Watch
Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.
News Placeholder
More News
News Placeholder
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
Sector ETF report for IYH
News Placeholder
Consumer Sentiment Weakens: ETFs That Are Worth a Look
Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.
News Placeholder
Stagflation Scare? ETFs May Help Protect Your Portfolio
Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.
News Placeholder
Middle East Turmoil and U.S. Debt Surge: ETFs in Focus
With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.
News Placeholder
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.
News Placeholder
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.
News Placeholder
Why Did IXHL Stock Tank Over 32% Today?
The company’s board approved a 1-for-30 reverse stock split, effective on February 26.
News Placeholder
Why Did GERN Stock Tumble 10% Pre-Market Today?
Total revenue reached $48 million for the fourth quarter, with a loss per share of $0.05, with both metrics coming in below street estimates.
News Placeholder
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today?
The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available